Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2001 2
2002 1
2003 4
2004 6
2005 6
2006 2
2007 1
2008 8
2009 6
2010 7
2011 7
2012 5
2013 8
2014 11
2015 12
2016 16
2017 14
2018 11
2019 19
2020 7
2021 21
2022 21
2023 20
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
Hettmer S, Linardic CM, Kelsey A, Rudzinski ER, Vokuhl C, Selfe J, Ruhen O, Shern JF, Khan J, Kovach AR, Lupo PJ, Gatz SA, Schäfer BW, Volchenboum S, Minard-Colin V, Koscielniak E, Hawkins DS, Bisogno G, Sparber-Sauer M, Venkatramani R, Merks JHM, Shipley J. Hettmer S, et al. Among authors: merks jhm. Eur J Cancer. 2022 Sep;172:367-386. doi: 10.1016/j.ejca.2022.05.036. Epub 2022 Jul 12. Eur J Cancer. 2022. PMID: 35839732 Free article. Review.
Response.
Meulepas JM, Ronckers CM, Smets AMJB, Nievelstein RAJ, Gradowska P, Lee C, Jahnen A, van Straten M, de Wit MY, Zonnenberg B, Klein WM, Merks JH, Visser O, van Leeuwen FE, Hauptmann M. Meulepas JM, et al. Among authors: merks jh. J Natl Cancer Inst. 2019 Apr 12;111(9):1002-3. doi: 10.1093/jnci/djz062. Online ahead of print. J Natl Cancer Inst. 2019. PMID: 30977817 Free PMC article. No abstract available.
Maintenance Chemotherapy for Patients with Rhabdomyosarcoma.
Bisogno G, Minard-Colin V, Jenney M, Ferrari A, Chisholm J, Di Carlo D, Hjalgrim LL, Orbach D, Merks JHM, Casanova M. Bisogno G, et al. Among authors: merks jhm. Cancers (Basel). 2023 Aug 7;15(15):4012. doi: 10.3390/cancers15154012. Cancers (Basel). 2023. PMID: 37568826 Free PMC article. Review.
Effects of a combined physical and psychosocial training for children with cancer: a randomized controlled trial.
Braam KI, van Dijk-Lokkart EM, Kaspers GJL, Takken T, Huisman J, Buffart LM, Bierings MB, Merks JHM, van den Heuvel-Eibrink MM, Veening MA, van Dulmen-den Broeder E. Braam KI, et al. Among authors: merks jhm. BMC Cancer. 2018 Dec 27;18(1):1289. doi: 10.1186/s12885-018-5181-0. BMC Cancer. 2018. PMID: 30587148 Free PMC article. Clinical Trial.
Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
Defachelles AS, Bogart E, Casanova M, Merks JHM, Bisogno G, Calareso G, Gallego Melcon S, Gatz SA, Le Deley MC, McHugh K, Probst A, Rocourt N, van Rijn RR, Wheatley K, Minard-Colin V, Chisholm JC. Defachelles AS, et al. Among authors: merks jhm. J Clin Oncol. 2021 Sep 20;39(27):2979-2990. doi: 10.1200/JCO.21.00124. Epub 2021 Aug 3. J Clin Oncol. 2021. PMID: 34343032 Clinical Trial.
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
Bisogno G, De Salvo GL, Bergeron C, Gallego Melcón S, Merks JH, Kelsey A, Martelli H, Minard-Colin V, Orbach D, Glosli H, Chisholm J, Casanova M, Zanetti I, Devalck C, Ben-Arush M, Mudry P, Ferman S, Jenney M, Ferrari A; European paediatric Soft tissue sarcoma Study Group. Bisogno G, et al. Among authors: merks jh. Lancet Oncol. 2019 Nov;20(11):1566-1575. doi: 10.1016/S1470-2045(19)30617-5. Epub 2019 Sep 24. Lancet Oncol. 2019. PMID: 31562043 Clinical Trial.
Biological Role and Clinical Implications of MYOD1L122R Mutation in Rhabdomyosarcoma.
Di Carlo D, Chisholm J, Kelsey A, Alaggio R, Bisogno G, Minard-Colin V, Jenney M, Dávila Fajardo R, Merks JHM, Shipley JM, Selfe JL. Di Carlo D, et al. Among authors: merks jhm. Cancers (Basel). 2023 Mar 7;15(6):1644. doi: 10.3390/cancers15061644. Cancers (Basel). 2023. PMID: 36980529 Free PMC article. Review.
Reply to H. B et al.
Defachelles AS, Bogart E, Casanova M, Merks JHM, Bisogno G, Calareso G, Melcon SG, Gatz SA, Le Deley MC, McHugh K, Probst A, Rocourt N, van Rijn RR, Minard-Colin V, Chisholm JC. Defachelles AS, et al. Among authors: merks jhm. J Clin Oncol. 2022 Mar 20;40(9):1030-1032. doi: 10.1200/JCO.21.02612. Epub 2022 Feb 7. J Clin Oncol. 2022. PMID: 35130027 No abstract available.
Brain tumors and syndromes in children.
Bleeker FE, Hopman SM, Merks JH, Aalfs CM, Hennekam RC. Bleeker FE, et al. Among authors: merks jh. Neuropediatrics. 2014 Jun;45(3):137-61. doi: 10.1055/s-0034-1368116. Epub 2014 Feb 17. Neuropediatrics. 2014. PMID: 24535705 Review.
190 results